LOGO.jpg
Celsion Corporation to Highlight its PLACCINE Platform Technology During Oral Presentation at the World Vaccine Congress
12 avr. 2022 08h30 HE | Celsion Corporation
LAWRENCEVILLE, N.J., April 12, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced...
LOGO.jpg
Celsion Corporation Announces Closing of $7.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
08 avr. 2022 16h30 HE | Celsion Corporation
LAWRENCEVILLE, NJ, April 08, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) (“Celsion” or the “Company”), today announced the closing of its previously announced registered direct...
LOGO.jpg
Celsion and Medidata to Present Findings on Use of Synthetic Control Arm to Estimate Treatment Effect in Ovarian Cancer Trial
06 avr. 2022 08h30 HE | Celsion Corporation
Phase Ib dose-escalating OVATION I Study with GEN-1 in advanced ovarian cancer patients to be presented at 2022 AACR Annual Meeting being held April 8-13 in New Orleans, LA LAWRENCEVILLE, N.J., April...
LOGO.jpg
CELSION CORPORATION ANNOUNCES $7.0 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET UNDER NASDAQ RULES
06 avr. 2022 08h30 HE | Celsion Corporation
LAWRENCEVILLE, NJ, April 06, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) (“Celsion” or the “Company”), today announced it has entered into definitive agreements with institutional...
LOGO.jpg
Celsion Corporation Reported Cash Position of $56.9 million at December 31, 2021
01 avr. 2022 08h00 HE | Celsion Corporation
LAWRENCEVILLE, N.J., April 01, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced...
LOGO.jpg
Celsion Corporation Reports 2021 Financial Results and Provides Business Update
31 mars 2022 08h30 HE | Celsion Corporation
Focus on Cancer Immunotherapy and Next-Generation Vaccines and a Strong Balance Sheet Conference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J., March 31, 2022 (GLOBE NEWSWIRE)...
LOGO.jpg
Celsion Corporation to Hold Year-End 2021 Financial Results and Business Update Conference Call on Thursday, March 31, 2022
24 mars 2022 09h00 HE | Celsion Corporation
LAWRENCEVILLE, N.J., March 24, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines,...
LOGO.jpg
Celsion Receives $1.4 Million from Sale of its New Jersey State Net Operating Losses
28 févr. 2022 09h00 HE | Celsion Corporation
Non-dilutive funding further strengthens balance sheet and extends current operating runway through 2024 Additional $3.5 million of unused state NOLs expected to be sold in future years ...
LOGO.jpg
Celsion Corporation Announces Stock Consolidation
28 févr. 2022 08h30 HE | Celsion Corporation
LAWRENCEVILLE, N.J., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced...
LOGO.jpg
Celsion Reports Data Safety Monitoring Board Unanimous Recommendation to Continue Dosing Patients in the Phase II Portion of the OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer
17 févr. 2022 08h30 HE | Celsion Corporation
OVATION 2 Study is Over 75% Enrolled; Full Enrollment Expected by Mid-2022 Novel Gene-Mediated Immunotherapy is Safe and Demonstrates an Acceptable Risk/Benefit When Administered Over...